Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303363 | 0.79 | PIN1 (0.59) | BRD4MPO | |
| SCHEMBL3300630 | 0.78 | MGMT (0.56) | MPOXDH | |
| SCHEMBL5197013 | 0.78 | BRD4 (0.46) | BRD4ACHEAPPMPOADORA3 | |
| SCHEMBL4102997 | 0.71 | ACHE (0.45) | BRD4ACHEAPPMPOADORA3 | |
| SCHEMBL11463436 | 0.69 | ADORA3 (0.60) | BRD4ADORA3ADORA1ALDH1A1MEN1 | |
| SCHEMBL3340079 | 0.69 | JAK2 (0.47) | ACHEAPPADORA3ALDH1A1PPIA | |
| SCHEMBL3334534 | 0.68 | DHODH (0.48) | BRD4ACHEAPPADORA3ADORA1 | |
| SCHEMBL21591842 | 0.68 | MPO (0.43) | BRD4MPOADORA3ADORA1PPARG | |
| SCHEMBL3338586 | 0.67 | ACHE (0.54) | ACHEAPPADORA3ALDH1A1MEN1 | |
| SCHEMBL21769255 | 0.67 | BRD4 (0.57) | BRD4ADORA3ADORA1PPIAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | disclosed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | disclosed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | BRD4 558/4885ACHE 4103/4885APP 4480/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | BRD4 577/4885ACHE 4128/4885APP 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.